Haemonetics Corporation

Report azionario NYSE:HAE

Capitalizzazione di mercato: US$4.7b

Haemonetics Crescita futura

Criteri Future verificati 4/6

Haemonetics prevede che gli utili e i ricavi cresceranno rispettivamente di 23.5% e 5.4% all'anno. Si prevede che l'EPS crescerà di 23.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 22.5% in 3 anni.

Informazioni chiave

23.5%

Tasso di crescita degli utili

23.82%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili17.0%
Tasso di crescita dei ricavi5.4%
Rendimento futuro del capitale proprio22.50%
Copertura analitica

Good

Ultimo aggiornamento03 Sep 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento narrativa • Sep 10

HAE: CSL Plasma Renewal And Vascular Closure Progress Will Shape FY27 Rerating Potential

Haemonetics' analyst fair value estimate has moved from $96.90 to $108.40 as analysts factor in higher Street price targets tied to the renewed CSL plasma supply agreement, NexSys PCS adoption, and the potential for what some describe as meaningful adjusted EPS upside if lost plasma business is gradually recaptured. Analyst Commentary Recent research commentary around Haemonetics has centered on the renewed CSL plasma relationship, the NexSys PCS platform and what these could mean for valuation, earnings power and execution over the next few years.
Aggiornamento narrativa • Aug 27

HAE: Recent Plasma Deal And High Expectations Will Drive Catalyst Fatigue Risk

Haemonetics' updated fair value estimate increases from $65.93 to $86.00 as analysts raise price targets into the $100 to $120 range, citing stronger support from plasma supply agreements, productivity benefits from NexSys PCS with Persona PLUS, and improved expectations for profitability and valuation multiples. Analyst Commentary Recent Street research on Haemonetics shows a cluster of higher price targets, generally in a US$90 to US$120 range, with most firms maintaining positive ratings.
Seeking Alpha • Aug 21

Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model

Summary Haemonetics is a medtech company that’s increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential. Lastly, I think HAE’s valuation still looks reasonable despite the impressive rally during 2026. So, while I reckon there’s less margin of safety today, HAE still looks compelling as a speculative “Buy” for long-term investors. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 12

HAE: FY27 Execution And Vascular Closure Advances Will Shape Rerating Potential

Haemonetics' analyst fair value estimate has increased by $10 to $96.90 as analysts respond to a series of higher price targets tied to Q1 beat and raise results, expectations for stronger FY27 performance, and ongoing optimism around profitability and debt reduction. Analyst Commentary Recent research on Haemonetics points to a broadly constructive view on the stock, with several bullish analysts lifting price targets following Q1 results and updated outlooks.
Aggiornamento narrativa • Jul 29

HAE: Recent Index Additions And Buybacks Will Face Catalyst Fatigue Risk

Haemonetics' analyst fair value estimate has moved from $62.00 to about $65.93 as analysts factor in recent price target increases tied to perceived Plasma and Hospital upside, sector model updates, and changing expectations around near-term catalysts. Analyst Commentary Recent research on Haemonetics shows a mix of optimism around Plasma and Hospital opportunities and caution around how much good news is already reflected in the stock.
Aggiornamento narrativa • Jun 24

HAE: Vascular Closure Optimism Will Face Ongoing Execution And Reporting Restructure Risk

Haemonetics enters this narrative update with a higher Street price target range, highlighted by Citi lifting its target to $70 from $64 and BofA raising its target to $80 from $72. Analysts reference updated medical technology models, a view that vascular closure may have turned a corner, and what they see as conservative guidance with potential upside across all three segments.
Aggiornamento narrativa • Jun 08

HAE: Vascular Closure Optimism Will Face Growing Concerns Over Execution Risk

Haemonetics' analyst price targets have shifted higher, with recent moves from $64 to $70 and from $72 to $80, as analysts point to solid sector fundamentals, a perceived turning point in vascular closure, and what they view as more durable plasma upside. Analyst Commentary Recent Street research on Haemonetics shows a mix of supportive and cautious views.
Articolo di analisi • May 27

Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings

The market for Haemonetics Corporation's ( NYSE:HAE ) shares didn't move much after it posted weak earnings recently...
Aggiornamento narrativa • May 25

HAE: Vascular Closure And Plasma Upside Will Offset Recent Cautious Repricing

Haemonetics' updated analyst price target has shifted from $64.00 to $62.00 as analysts balance slightly adjusted fair value and profitability assumptions with views that potential upside to guidance in vascular closure and plasma could prove more durable over time. Analyst Commentary Recent Street research on Haemonetics reflects a mix of optimism around vascular closure and plasma, alongside a series of lower price targets that highlight ongoing execution and growth questions.
Aggiornamento narrativa • May 09

HAE: New Approvals And Trials Will Support Upside Despite Cautious Repricing

Haemonetics' updated analyst price target reflects a modest reset in expectations, with several firms trimming their targets by $4 to $12 as analysts factor in slightly lower revenue growth assumptions, a marginally higher profit margin outlook, and a small adjustment to the assumed future P/E multiple. Analyst Commentary Recent research shows a cluster of bearish adjustments to Haemonetics' price targets, with several bearish analysts trimming their numbers in close succession.
Aggiornamento narrativa • Apr 22

HAE: Pipeline And Product Updates Will Offset Cautious Sector Repricing

Haemonetics' implied fair value price target has been revised to $64 from $70 as analysts factor in updated sector peer multiples, adjustments to revenue growth and margin assumptions, and a slightly higher discount rate following recent Street research updates. Analyst Commentary Recent Street research around Haemonetics reflects a more cautious tone as several bearish analysts trim their price targets and revisit their assumptions on growth, margins, and valuation risk.
Aggiornamento narrativa • Apr 08

HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing

Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.
Aggiornamento narrativa • Mar 25

HAE: Vivasure Deal And Pipeline Progress Will Support Future Share Recovery

Analysts have reduced the Haemonetics fair value estimate to $70 from $74. Recent target resets in the group, including Citi's move to $70, reflect updated assumptions around growth, margins and the P/E multiple for the stock.
Aggiornamento narrativa • Mar 10

HAE: Vivasure Deal And 2026 Outlook Will Support Earnings Quality

Analysts have modestly adjusted their views on Haemonetics, with several firms trimming price targets by $10 to $18 and one small $1 upward revision. These changes reflect updated assumptions on valuation multiples, while fair value and key model inputs remain broadly unchanged.
Aggiornamento narrativa • Feb 23

HAE: Vivasure Acquisition And FY26 Outlook Will Support Margin Recovery

The analyst price target for Haemonetics has been reduced by $3.70, with analysts pointing to a slightly higher discount rate, a lower fair value estimate and some pressure on projected profit margins, even as they continue to apply a higher forward P/E and updated revenue growth assumptions in their models. Analyst Commentary Recent Street research on Haemonetics has been mixed, with several firms trimming their price targets while at least one firm has lifted its target in connection with the Vivasure Medical acquisition.
Aggiornamento narrativa • Feb 08

HAE: Vivasure Acquisition Will Drive Execution And Support Future Share Recovery

Analysts have trimmed their fair value estimate for Haemonetics to about $74.00, reflecting mixed Street price target moves that weigh recent target cuts from several firms against at least one increase tied to a favorable view of the Vivasure Medical acquisition. Analyst Commentary Recent Street research around Haemonetics reflects a split view, with several bearish analysts trimming price targets and a smaller group seeing upside tied to the Vivasure Medical acquisition.
Aggiornamento narrativa • Jan 25

HAE: Vivasure Deal And Buyback Will Shape Execution And Share Recovery

Analysts have lifted their price target for Haemonetics from about $58 to roughly $74.82, citing recent Street research that points to higher assumed revenue growth, slightly stronger profit margins, a higher future P/E, and supportive views on the Vivasure acquisition and recent earnings execution. Analyst Commentary Recent Street research has centered on two main themes for Haemonetics, the Vivasure acquisition and the company’s latest earnings print.
Aggiornamento narrativa • Jan 11

HAE: Achievable Hospital Reset And FY26 Outlook Will Support Gradual Recovery

Narrative Update on Haemonetics Analysts have inched up their price target for Haemonetics, with updated fair value rising from about US$90 to roughly US$92, citing recent price target increases, company performance that met or exceeded expectations across segments, and what they view as more achievable guidance and improved credibility on execution and messaging. Analyst Commentary Recent commentary has focused on how Haemonetics is executing against expectations, how realistic its guidance looks, and what that might mean for valuation support and potential growth in the medium term.
Articolo di analisi • Jan 06

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Aggiornamento narrativa • Dec 24

HAE: Achievable Hospital Guidance Reset Will Support Gradual Share Recovery

Analysts have modestly raised their price target on Haemonetics to approximately $90 from about $86, citing stronger than expected execution across all segments, a more achievable Hospital guidance reset, and an improved long term sales outlook that supports higher growth and valuation assumptions. Analyst Commentary Analysts see the recent quarter as a constructive inflection point for Haemonetics, with improved guidance and execution supporting a modestly higher valuation framework, though some caution remains around sustainability of growth and delivery against new targets.
Aggiornamento narrativa • Dec 10

HAE: Broad Outperformance And Achievable Hospital Guidance Will Support Gradual Share Recovery

Analysts have modestly raised their price target on Haemonetics to approximately $86 from about $85, citing broad-based outperformance, more achievable Hospital guidance, and an upgraded FY26 sales outlook that supports a gradual recovery in the shares. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the price target increase toward the high $80s reflects growing confidence in the company’s ability to sustain outperformance across all operating segments.
Aggiornamento narrativa • Nov 26

HAE: Solid Execution And Achievable Guidance Will Support Measured Share Recovery

Analysts have raised their price target for Haemonetics from $83 to approximately $84.55. They cite solid execution, an improved sales outlook, and increased confidence in the company's guidance and operational credibility.
Aggiornamento narrativa • Nov 12

HAE: Upbeat Execution And Reset Guidance Should Drive Share Price Recovery

Haemonetics' analyst price target has been raised from $76.27 to $83.00, as analysts cite improved execution, strong segment performance, and a more optimistic sales outlook as key drivers for the upward revision. Analyst Commentary Following recent quarterly results and the revised price target, analysts have shared both optimistic highlights and points of caution regarding Haemonetics' outlook and valuation.
Articolo di analisi • Nov 07

A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb

Haemonetics Corporation ( NYSE:HAE ) shares have had a really impressive month, gaining 36% after a shaky period...
Aggiornamento narrativa • Oct 28

Execution Challenges Will Shift Outlook For Global Plasma And Hemostasis Expansion

Haemonetics’ analyst price target has been revised lower by analysts to approximately $76 from $77. This change reflects concerns about execution within the Interventional Technologies segment, despite confidence in the company’s long-term value.
Aggiornamento narrativa • Oct 14

Aging Demographics Will Expand Global Plasma And Hemostasis Markets

The analyst price target for Haemonetics has been lowered by approximately $1.73 to $76.91. Analysts cite ongoing concerns around sales execution and challenges in the Interventional Technologies segment.
Articolo di analisi • Sep 15

Is Haemonetics Corporation (NYSE:HAE) Trading At A 48% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Haemonetics fair value estimate is US$100 Haemonetics...
Aggiornamento narrativa • Aug 08

Aging Demographics Will Expand Global Plasma And Hemostasis Markets

The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18. What's in the News Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index Valuation Changes Summary of Valuation Changes for Haemonetics The Consensus Analyst Price Target has fallen from $92.45 to $85.18.
Articolo di analisi • Aug 08

Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower

Haemonetics Corporation ( NYSE:HAE ) shareholders won't be pleased to see that the share price has had a very rough...
Articolo di analisi • Jun 30

Haemonetics (NYSE:HAE) Seems To Use Debt Quite Sensibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Articolo di analisi • Jun 10

Market Participants Recognise Haemonetics Corporation's (NYSE:HAE) Earnings

Haemonetics Corporation's ( NYSE:HAE ) price-to-earnings (or "P/E") ratio of 20.5x might make it look like a sell right...
Articolo di analisi • May 10

Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Articolo di analisi • Mar 18

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Feb 20

Haemonetics: Almost Blood In The Streets

Summary Haemonetics shares have been trading at more appealing levels after a reduction in full-year sales guidance, trading at historically reasonable levels. The company, generating $1.3 billion in annual sales, has seen modest growth, with significant contributions from its plasma and hospital segments. Despite a cautious outlook due to suboptimal positioning in some units, Haemonetics aims for continued growth in 2025, aided by M&A efforts. Shares have fallen to $64, valuing the business at 3 times sales, with adjusted earnings multiples dropping to mid-teens multiple. The appeal is improving here. Read the full article on Seeking Alpha
Articolo di analisi • Feb 13

Haemonetics (NYSE:HAE) Is Posting Promising Earnings But The Good News Doesn’t Stop There

The market seemed underwhelmed by the solid earnings posted by Haemonetics Corporation ( NYSE:HAE ) recently. Our...
Articolo di analisi • Dec 06

Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings

Haemonetics Corporation's ( NYSE:HAE ) price-to-earnings (or "P/E") ratio of 32.7x might make it look like a strong...
Articolo di analisi • Sep 09

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
User avatar
Nuova narrativa • Sep 03

Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth

Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.
Articolo di analisi • Aug 14

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...
Articolo di analisi • Jul 18

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Key Insights The projected fair value for Haemonetics is US$167 based on 2 Stage Free Cash Flow to Equity Haemonetics...
Seeking Alpha • Jun 21

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter vascular closure, but recent M&A deals have been more questionable. Haemonetics should see revenue reacceleration in FY'26, with long-term revenue growth of 6% to 7% and margin improvement driving a fair value above $100. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NYSE:HAE - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
3/31/20291,5802403583936
3/31/20281,48920733536911
3/31/20271,41517731735111
6/27/20261,35296291328N/A
3/28/20261,33497260293N/A
12/27/20251,318175308339N/A
9/27/20251,328168256289N/A
6/28/20251,346163189227N/A
3/29/20251,361168142182N/A
12/28/20241,37413099129N/A
9/28/20241,3611244985N/A
6/29/20241,33411599135N/A
3/30/20241,309118144182N/A
12/30/20231,270127154197N/A
9/30/20231,239128217262N/A
7/1/20231,219137178250N/A
4/1/20231,16911582273N/A
12/31/20221,12996128261N/A
10/1/20221,08486116260N/A
7/2/20221,0266888216N/A
4/2/20229934376172N/A
1/1/20229532333106N/A
10/2/20219343154110N/A
7/3/2021903645295N/A
4/3/20218707972109N/A
12/26/2020884108118154N/A
9/26/2020903106120167N/A
6/27/202094696119167N/A
3/28/202098877N/A158N/A
12/28/201999980N/A132N/A
9/28/201998868N/A111N/A
6/29/201997749N/A139N/A
3/30/201996855N/A159N/A
12/29/201895246N/A196N/A
9/29/201893921N/A204N/A
6/30/201892223N/A205N/A
3/31/201890446N/A220N/A
12/30/2017898-17N/A197N/A
9/30/20178924N/A187N/A
7/1/20178874N/A167N/A
4/1/2017886-26N/A160N/A
12/31/201690016N/A178N/A
10/1/2016906-59N/A155N/A
7/2/2016905-66N/A143N/A
4/2/2016909-56N/A122N/A
12/26/2015893-50N/A124N/A
9/26/201589126N/A119N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di HAE ( 23.5% all'anno) è superiore al tasso di risparmio ( 3.7% ).

Guadagni vs Mercato: Si prevede che gli utili di HAE ( 23.5% all'anno) cresceranno più rapidamente del mercato US ( 17.2% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di HAE cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di HAE ( 5.4% all'anno) crescerà più lentamente rispetto al mercato US ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di HAE ( 5.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di HAE sarà elevato tra 3 anni ( 22.5 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/09/13 20:48
Prezzo dell'azione a fine giornata2026/09/11 00:00
Utili2026/06/27
Utili annuali2026/03/28

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Haemonetics Corporation è coperta da 24 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David RescottBaird
Michael PetuskyBarrington Research Associates, Inc.
Travis SteedBofA Global Research